ELOX · Eloxx Pharmaceuticals, Inc. · Metrics
$15.75
-0.53 (-3.26%)
At close · Sep 11
Going-concern doubt
— cleared Aug 11, 2026
The latest filing no longer states the doubt (first flagged May 5, 2026).
View the 10-Q filed Aug 11, 2026Market Cap
$63.57M
Shares
4.04M
ELOX metrics
40 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$15.75
Market cap
$63.57M
Price action
20 metricsPrice change (1W)
+5.0%
Price change (30D)
-17.4%
Price change (3M)
+16.5%
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
126.0%
Annualized volatility (3M)
124.8%
Beta
—
RSI (14D)
47.6
Price vs SMA 50
+3.0%
Price vs SMA 200
—
Avg volume (3M)
52,742
Relative volume
0.3
Average dollar volume
$771,490
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
4.04M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
1.4
reciprocal yield 73.0%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-16.8%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2021-11-09
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$11.88M
Net income (TTM)
−$10.65M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1,856.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-22.9%
Return on assets
-16.8%
Debt / equity
—
Current ratio
3.7
EBITDA (TTM)
−$3.96M
Free cash flow (TTM)
—
Quick ratio
3.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$61.96M
Total assets
$63.39M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$16.02M
Capital expenditures (TTM)
$0
R&D (TTM)
$6.15M
SG&A (TTM)
—
Stock compensation (TTM)
$340,000
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
22
13F filer change QoQ
+22
Institutional ownership
61.9%
Short interest
3 metricsShort interest
0.7%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
46 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—